Beryl Leirvaag's picture

Beryl Leirvaag

Head Engineer

Department of Clinical Science

E-mailBeryl.Leirvaag@uib.no
Phone+47 55 97 64 44
Visitor Address
Haukeland universitetssykehus, Laboratoriebygget

5009 Bergen
Postal Address
Postboks 7804

5020 Bergen

Publications

Academic article

Show author(s) (2023). Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development. Genome Medicine. 15 pages.
Show author(s) (2023). Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer. JCO Precision Oncology (JCO PO). 10 pages.

Show author(s) (2020). Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Annals of Oncology. 1-10.

Show author(s) (2016). Prevalence of the CHEK2 R95* germline mutation. Hereditary Cancer in Clinical Practice. 4 pages.

Show author(s) (2015). Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo. Molecular Oncology. 1553-1564.

Show author(s) (2012). Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Research. 12 pages.

More information in national current research information system (CRIStin)